We are live on ! Find out more
PLRX icon

Pliant Therapeutics
PLRX

151 hedge funds and large institutions have $725M invested in Pliant Therapeutics in 2024 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 60 increasing their positions, 31 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

94% more repeat investments, than reductions

Existing positions increased: 60 | Existing positions reduced: 31

50% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 16

6% more capital invested

Capital invested by funds: $687M → $725M (+$38.5M)

6% more funds holding

Funds holding: 143 → 151 (+8)

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

1.48% less ownership

Funds ownership: 105.91% → 104.43% (-1.5%)

74% less call options, than puts

Call options by funds: $1.31M | Put options by funds: $4.99M

Holders
151
Holders Change
+8
Holders Change %
+5.59%
% of All Funds
2.17%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
24
Increased
60
Reduced
31
Closed
16
Calls
$1.31M
Puts
$4.99M
Net Calls
-$3.68M
Net Calls Change
-$4.06M

Top Buyers

Rank Fund Capital Flow
1
PBA
Paradigm Biocapital Advisors
New York
+$38.8M
2
IHAM
Integral Health Asset Management
New York
+$3.75M
3
BlackRock
BlackRock
New York
+$3.09M
4
ACM
ADAR1 Capital Management
Texas
+$2.95M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$2.91M

Top Sellers

Rank Fund Capital Flow
1
LCM
Laurion Capital Management
New York
-$26.9M
2
CC
Casdin Capital
New York
-$10.8M
3
FLAM
First Light Asset Management
Minnesota
-$10.3M
4
GPP
Great Point Partners
Connecticut
-$9.09M
5
Citadel Advisors
Citadel Advisors
Florida
-$4.95M
Name Holding Trade Value Shares
Change 		Change in
Stake
Northern Trust
26
Northern Trust
Illinois
$5.63M +$311K +24,851 +5%
Charles Schwab
27
Charles Schwab
California
$5.12M +$241K +19,281 +4%
Dimensional Fund Advisors
28
Dimensional Fund Advisors
Texas
$5.11M +$1.89M +150,844 +49%
Barclays
29
Barclays
United Kingdom
$4.73M +$983K +78,575 +23%
RSCM
30
Rock Springs Capital Management
Maryland
$4.32M – – –
CC
31
Checkpoint Capital
California
$4.26M +$1.85M +147,800 +64%
Axa
32
Axa
France
$3.9M +$1.23K +98 +0%
Goldman Sachs
33
Goldman Sachs
New York
$3.89M +$1.68M +134,159 +63%
IHAM
34
Integral Health Asset Management
New York
$3.36M +$3.75M +300,000 New
SFM
35
Sphera Funds Management
Israel
$3.33M +$486K +38,808 +15%
MGB
36
Mass General Brigham
Massachusetts
$3.24M – – –
ACH
37
ArrowMark Colorado Holdings
Colorado
$3.15M – – –
ACM
38
ADAR1 Capital Management
Texas
$2.76M +$2.95M +236,128 +2,361%
Millennium Management
39
Millennium Management
New York
$2.74M +$2.14M +171,350 +234%
UBS Group
40
UBS Group
Switzerland
$2.58M +$977K +78,106 +51%
Capital International Investors
41
Capital International Investors
California
$2.52M – – –
Jane Street
42
Jane Street
New York
$2.09M -$635K -50,772 -21%
Bank of New York Mellon
43
Bank of New York Mellon
New York
$2.07M -$552K -44,139 -19%
PAMP
44
Polar Asset Management Partners
Ontario, Canada
$1.91M +$1.55M +123,600 +265%
Two Sigma Advisers
45
Two Sigma Advisers
New York
$1.77M -$399K -31,900 -17%
RHJA
46
Rice Hall James & Associates
California
$1.76M +$370K +29,583 +23%
EAM
47
Exome Asset Management
New York
$1.68M +$320K +25,600 +21%
Two Sigma Investments
48
Two Sigma Investments
New York
$1.51M -$1.38M -110,450 -45%
RPAM
49
Rhenman & Partners Asset Management
Sweden
$1.35M – – –
UBS AM
50
UBS AM
Illinois
$1.32M +$5.69K +455 +0.4%
1
2
3 4 5

PLRX Hedge Fund Activity: Q3 2024 in Review

151 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Pliant Therapeutics (PLRX) for Q3 2024, worth a combined $725M — up 5.6% from $687M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new PLRX positions and 16 closed out — a net gain of 8 holders — while 60 added to existing stakes and 31 trimmed.

The largest buyer was Paradigm Biocapital Advisors, opening a new position worth an estimated $38.8M. The largest seller was Laurion Capital Management, exiting entirely with an estimated $26.9M sold.

  • 151 institutional investors held Pliant Therapeutics (PLRX) as of Q3 2024, up from 143 in Q2 2024.
  • Funds reported $725M of Pliant Therapeutics stock for Q3 2024, up 5.6% quarter-over-quarter.
  • 24 funds opened new Pliant Therapeutics positions in Q3 2024 and 16 closed out, a net change of +8 holders.
  • The largest Pliant Therapeutics buyer in Q3 2024 was Paradigm Biocapital Advisors, an estimated $38.8M added.
  • The largest Pliant Therapeutics seller in Q3 2024 was Laurion Capital Management, an estimated $26.9M sold.

Based on aggregated 13F filings for Q3 2024.